OSR Health (OSRHW) Net Income towards Common Stockholders (2022 - 2026)
OSR Health (OSRHW) posted Net Income towards Common Stockholders of -$2.9 million for Q1 2026, up 39.22% sequentially from -$4.8 million in Q4 2025, and up 74.27% YoY from -$1.7 million in Q1 2025.
OSR Health (OSRHW) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
OSR Health has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$2.9 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 74.27% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.5 million (up 48.01% YoY) and the FY2025 annual result came in at -$18.0 million, down 74.37% from the prior year.
- Net Income towards Common Stockholders rose to -$2.9 million in Q1 2026 per OSRHW's latest filing, from -$4.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $331414.0 in Q2 2025 and troughed at -$11.4 million in Q1 2025.
- A 5-year average of -$1.9 million and a median of -$712847.5 in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 30612.55% in 2023, then slumped 4393.17% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$14252.0 in 2022, then plunged by 504.63% to -$86172.0 in 2023, then slumped by 1454.48% to -$1.3 million in 2024, then tumbled by 260.05% to -$4.8 million in 2025, then surged by 39.22% to -$2.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.9 million, -$4.8 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.12 Bn | 131.27 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.30 Bn | 77.31 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.66 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 55.67 Bn | 50.53 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.43 Bn | 36.33 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.47 Bn | 9.08 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.03 Bn | 25.87 Bn | 358.27 Mn | -13.27 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | -848,905.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.93 Mn |
| Dec 31, 2025 | -4.82 Mn |
| Sep 30, 2025 | -2.13 Mn |
| Jun 30, 2025 | 331,414.00 |
| Mar 31, 2025 | -11.39 Mn |
| Dec 31, 2024 | -1.34 Mn |
| Sep 30, 2024 | -3.36 Mn |
| Jun 30, 2024 | -2.28 Mn |
| Mar 31, 2024 | -3.36 Mn |
| Dec 31, 2023 | -86,172.00 |
| Sep 30, 2023 | 78,183.00 |
| Jun 30, 2023 | 301,464.00 |
| Mar 31, 2023 | 110,305.00 |
| Dec 31, 2022 | -14,252.00 |
| Sep 30, 2022 | -20,022.00 |
| Jun 30, 2022 | -988.00 |